Concurrent sexual partnerships help to explain Africa's high HIV prevalence: implications for prevention.

1 Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60. 2 Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in Southern India. Clin Infect Dis 2003; 36: 79–85. 3 Remien RH, Bastos FI, Berkman A, Terto V Jr, Raxach JC, Parker RG. Universal access to antiretroviral therapy may be the best approach to ‘Do no harm’ in developing countries: the Brazilian experience. AIDS 2003; 17: 786–87. 4 Kumarasamy N, Solomon S, Chaguturu S, et al. The safety , tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003; 17: 2267–69. 5 Hosseinipour M, Namarika D, Magomero K, et al. The Malawian antiretroviral program: the first year experience with Triomune. 10 conference on retroviruses and opportunistic infections, Boston, Feb 10–14, 2003: 172 (abstr). 6 Henry K, Brundage R, Weller D, Akinsete O, Shet A. Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithkline Brand (Combivir) tablets. J Acquir Immune Defic Syndr 2004; 35: 537. 7 Kumarasamy N, Flanigan TP, Solomon S, et al. Rapid viral load suppression following generic HAART in Southern Indian HIV-infected patients. XV International AIDS Conference, Bangkok, Thailand, July 11–16, 2004: ThPeB7137 (abstr). 8 Chesney M. Adgerence to HAART regimens. AIDS Patient Care STD 2003; 17: 169–77.